Immune checkpoint therapy—current perspectives and future directions

Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, Bilal A. Siddiqui, Pratishtha Singh, Ashwat Nagarajan, Jielin Liu, Sumit K. Subudhi, Candice Poon, Kristal L. Gant, Shelley M. Herbrich, Swetha Anandhan, Shajedul Islam, Moran Amit, Gayathri Anandappa, James P. Allison

Research output: Contribution to journalReview articlepeer-review

73 Scopus citations

Abstract

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types and the need for predictive biomarkers to optimize patient selection to maximize efficacy and minimize toxicities prompted efforts to unravel immune and non-immune factors regulating the responses to ICT. This review highlights the biology of anti-tumor immunity underlying response and resistance to ICT, discusses efforts to address the current challenges with ICT, and outlines strategies to guide the development of subsequent clinical trials and combinatorial efforts with ICT.

Original languageEnglish (US)
Pages (from-to)1652-1669
Number of pages18
JournalCell
Volume186
Issue number8
DOIs
StatePublished - Apr 13 2023

Keywords

  • combinatorial biomarkers
  • CTLA-4
  • cytotoxic T lymphocyte-associated protein 4
  • ICT
  • immune checkpoint therapy
  • immune-related adverse events
  • irAEs
  • PD-1
  • PD-L1
  • programmed cell death protein 1
  • programmed death ligand 1
  • reverse translation

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Immune checkpoint therapy—current perspectives and future directions'. Together they form a unique fingerprint.

Cite this